GlassScriptPhysician profile
Clifton Blayne Thomas
NPI 1659799757
$4,749.05
in general payments reported to CMS, 2019-2025
37 companies · $314 in 2025
The $314 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $827 · 2020: $877 · 2021: $1,488 · 2022: $868 · 2023: $184 · 2024: $191 · 2025: $314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $689.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $689.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $912.09 | 2019-2025 | |
| Novo Nordisk INC | $484.76 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $310.68 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $239.59 | 2019-2024 | Xarelto |
| Lilly USA, LLC | $233.37 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $230.60 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $205.89 | 2019-2022 | |
| Amarin Pharma, INC. | $196.25 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $195.68 | 2019-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $174.58 | 2020-2022 | |
| Dexcom, INC. | $163.84 | 2021-2025 | Dexcom G6 Transmitter |
| Biohaven Pharmaceuticals, INC. | $145.73 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $131.85 | 2020-2022 | |
| Astellas Pharma US INC | $125.07 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $116.34 | 2019-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $103.60 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $87.98 | 2022 | |
| Glaxosmithkline, LLC. | $84.96 | 2019-2021 | |
| Allergan, INC. | $82.42 | 2019-2020 | |
| Gilead Sciences, INC. | $63.66 | 2019 | |
| Esperion Therapeutics, INC. | $45.94 | 2021-2022 | |
| Eisai INC. | $43.97 | 2021 | |
| Avanir Pharmaceuticals, INC. | $42.72 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $37.29 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $33.40 | 2022 | |
| Sunovion Pharmaceuticals INC. | $31.12 | 2021-2022 | |
| Bausch Health US, LLC | $30.66 | 2020-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $30.15 | 2024-2025 | Lifevest |
| Idorsia Pharmaceuticals US INC | $26.92 | 2022-2023 | Quviviq |
| Sanofi-Aventis U.S. LLC | $24.05 | 2021 | |
| Abbott Laboratories | $20.19 | 2021 | |
| Medtronic, INC. | $17.93 | 2022 | |
| Xeris Pharmaceuticals, INC. | $16.63 | 2021 | |
| Insulet Corporation | $15.39 | 2022 | |
| Dermira, INC. | $15.26 | 2021 | |
| Genentech USA, INC. | $15.14 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $13.35 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clifton Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.